SCHEMBL6404498

SCHEMBL6404498

Cc1ccc(C(=O)NCCN2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)cc1[N+](=O)[O-]

nearest known ligand 0.66

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CCR3 P51677 3/20 0.66
HRH1 P35367 3/20 0.49
KCNH2 Q12809 1/20 0.49
HRH3 Q9Y5N1 4/20 0.49
LMNA P02545 5/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
MEN1 O00255 1/20 0.48
GAA P10253 1/20 0.48
MAPT P10636 1/20 0.48
HTT P42858 1/20 0.48
KMT2A Q03164 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
UTS2R Q9UKP6 2/20 0.47
ALDH1A1 P00352 3/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
HPGD P15428 1/20 0.47
PLD2 O14939 1/20 0.46
PLD1 Q13393 1/20 0.46
SLC5A7 Q9GZV3 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6399898 0.93 CCR3 (0.67) CCR3HRH1KCNH2HRH3LMNA
SCHEMBL6395839 0.87 CCR3 (0.66) CCR3HRH1KCNH2HRH3MAPT
SCHEMBL6397002 0.86 CCR3 (0.78) CCR3HRH1KCNH2HRH3UTS2R
SCHEMBL6399429 0.85 CCR3 (0.74) CCR3HRH1KCNH2HRH3KMT2A
SCHEMBL6403978 0.85 CCR3 (0.66) CCR3HRH1KCNH2HRH3MAPT
SCHEMBL6403935 0.84 CCR3 (0.73) CCR3HRH1KCNH2HRH3LMNA
SCHEMBL6397121 0.83 CCR3 (0.61) CCR3HRH1KCNH2MEN1KMT2A
SCHEMBL6397907 0.82 CCR3 (0.82) CCR3HRH1KCNH2HRH3LMNA
SCHEMBL6397226 0.82 CCR3 (0.72) CCR3HRH1KCNH2HRH3UTS2R
SCHEMBL6401584 0.82 CCR3 (0.78) CCR3HRH1KCNH2HRH3KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030134840-A1 Novel compounds ASTRAZENECA AB, A SWEDEN CORPORATION 2003-07-17 US claimed
US-6518286-B1 Piperidinyl compounds for modulation of immune and inflammatory responses in various diseases and disorders, including asthma ASTRAZENECA AB (SE) 2003-02-11 US claimed
JP-2002540204-A 2002-11-26 JP claimed
EP-1165545-A1 NOVEL COMPOUNDS AstraZeneca AB (SE) 2002-01-02 EP claimed
WO-2000058305-A1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2000-10-05 WO claimed
US-6946478-B2 Compounds ASTRAZENECA AB (SE) 2005-09-20 US disclosed
US-20030134840-A1 Novel compounds ASTRAZENECA AB, A SWEDEN CORPORATION 2003-07-17 US disclosed
US-6518286-B1 Piperidinyl compounds for modulation of immune and inflammatory responses in various diseases and disorders, including asthma ASTRAZENECA AB (SE) 2003-02-11 US disclosed
EP-1165545-A1 NOVEL COMPOUNDS AstraZeneca AB (SE) 2002-01-02 EP disclosed
WO-2000058305-A1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2000-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030134840-A1 Novel compounds RPS4X, RPS4Y1, CYP4B1 CCR3 894/4885HRH1 802/4885KCNH2 1627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.